A major enhancement for OCELLOS 3.0 is the ability to deal with multiple indications and multiple patient populations for each therapy. This allows stakeholders to manage all indications, patient groups or trials associated with a therapy from a single TrakCel platform. Data can also be segregated as needed, for example where different sponsors or supply chain partners are involved, reducing challenges of data privacy and control management. The enhancement enables all those involved in the development and delivery of therapies clinically progressing through multiple indications to have a single viewpoint and workflow across the supply and value chains. As a result, TrakCel’s OCELLOS platform considerably simplifies task management for stakeholders and partners, as information is consolidated into a single dashboard.
TrakCel has added this function to the ‘therapy switcher’ functionality that will remain in OCELLOS 3.0 and allows developers to manage different classes of therapy within the platform. The features have been combined so developers can manage their whole pipeline of therapies efficiently from a single platform to minimise cost of ownership, training and validation burdens.
Additionally, supply and value chains are continuing to internationalise as more companies launch into the CGT sector from different regions and countries. TrakCel has therefore developed the OCELLOS 3.0 user interface to manage multiple time zones and languages more intuitively. This makes it easier for a user to view, schedule and manage global manufacturing and logistics, over multiple manufacturing cycles, across a range of local languages, suppliers and time zones. OCELLOS 3.0 will continue to manage different processes, suppliers, patient populations and the chain of identity, labelling and data privacy obligations automatically from one platform.
OCELLOS 3.0 also includes the ability to model commercial relationships between healthcare providers and authorised apheresis/cell collection facilities. This increases the sustainability of the complex logistics networks that are needed to facilitate scale-up by only presenting users with an option of partners such as couriers and healthcare facilities that are authorised to deal with their patient, site or therapy.
“As TrakCel’s core orchestration platform within a rapidly evolving industry, OCELLOS has been designed to be well positioned to meet the needs of the cell and gene therapy industry as they grow and change. TrakCel is releasing new versions of the platform to ensure that customers can quickly add the newly developed features and functions to their system when they are needed, rather than having to develop them reactively. As a result, TrakCel is always working with clients and partners to anticipate and respond to market trends and apply them to the development of its product roadmap,” said Ravi Nalliah, Chief Product and Strategy Officer. “With the market focusing on scale up and commercialisation, TrakCel continues to work with customers and partners to support and facilitate the differing demands of commercial supply and value chains, whether the challenges relate to increasing patient numbers, broadening geographies or wider product sets. Developers are broadening their pipelines, and, now, many have several promising therapy candidates in development or approval. This makes it critical for sustainability that multiple candidates can be managed effectively on a single orchestration platform.”
TrakCel launched OCELLOS in 2021 as a significant market advancement against less flexible traditionally coded orchestration solutions. TrakCel has designed OCELLOS to be a Software-as-a-Service platform with a modular build. This accommodates the need for processes to change, or functionality to be added easily in order to meet supply chain changes as therapies mature. The OCELLOS platform has moved TrakCel away from custom-written code which took more time to alter, develop and maintain, and delivered the flexibility demanded by the CGT sector.
